These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7620602)

  • 41. Efficacy of a new sustained release procainamide preparation: evaluation with 24-hour Holter monitoring.
    Garcia JR; Godley ML; Freedman RJ
    J La State Med Soc; 1982; 134(1):8-9. PubMed ID: 7086265
    [No Abstract]   [Full Text] [Related]  

  • 42. Critical questions concerning nifedipine extended release formulations.
    Woodcock BG
    Int J Clin Pharmacol Ther; 2010 Jun; 48(6):355. PubMed ID: 20497743
    [No Abstract]   [Full Text] [Related]  

  • 43. Clinical use of sustained-release procainamide in treatment of cardiac arrhythmias.
    Michelson EL; McGeehin FC; Levin BK
    Angiology; 1988 Jul; 39(7 Pt 2):647-54. PubMed ID: 3044199
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-substitution of nifedipine slow-release preparations.
    Van Veenhuyzen D; Coetzee R
    S Afr Med J; 2002 Nov; 92(11):838, 840. PubMed ID: 12506575
    [No Abstract]   [Full Text] [Related]  

  • 45. [Serum concentrations of procainamide during treatment with ordinary and sustained-release tablets].
    Henningsen P; Laursen HB; Christiansen BD; Moller J
    Ugeskr Laeger; 1976 Sep; 138(40):2433-7. PubMed ID: 968997
    [No Abstract]   [Full Text] [Related]  

  • 46. Conventional and sustained-release procainamide: update on pharmacology and clinical use.
    Anderson JL
    Clin Ther; 1985; 7(5):618-40. PubMed ID: 3902240
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Severe neutropenia associated with procainamide: comparison of sustained release and conventional preparations.
    Meyers DG; Gonzalez ER; Peters LL; Davis RB; Feagler JR; Egan JD; Nair CK
    Am Heart J; 1985 Jun; 109(6):1393-5. PubMed ID: 4003250
    [No Abstract]   [Full Text] [Related]  

  • 48. Experiences on a sustained-release procainamide preparation.
    Ruosteenoja R; Torsti P; Sothmann A
    Curr Ther Res Clin Exp; 1973 Oct; 15(10):707-12. PubMed ID: 4201315
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmaceutical and pharmacokinetic principles in the formulation of a sustained-release procainamide tablet.
    Dahl SG; Fremstad D; Jacobsen S; Kvaleid I; Landmark KH; Lunde PK; Marthinsen AA; Nådland KJ; Waaler T
    Pharm Acta Helv; 1976; 51(7-8):204-8. PubMed ID: 967912
    [No Abstract]   [Full Text] [Related]  

  • 50. Gastric bezoar complicating laparoscopic adjustable gastric banding, and review of literature.
    White NB; Gibbs KE; Goodwin A; Teixeira J
    Obes Surg; 2003 Dec; 13(6):948-50. PubMed ID: 14738689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pure red cell aplasia associated with administration of sustained-release procainamide.
    Giannone L; Kugler JW; Krantz SB
    Arch Intern Med; 1987 Jun; 147(6):1179-80. PubMed ID: 3036033
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Agranulocytosis due to new sustained-release procainamide.
    Berger BE; Hauser DJ
    Am Heart J; 1983 Jun; 105(6):1035-6. PubMed ID: 6858823
    [No Abstract]   [Full Text] [Related]  

  • 53. Procainamide absorption studies to test the feasibility of using a sustained-release preparation.
    Shaw TR; Kumana CR; Kaye CM; Padgham C; Kaspi T; Hamer J
    Br J Clin Pharmacol; 1975 Dec; 2(6):515-9. PubMed ID: 1234015
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conversion from intravenous procainamide to oral sustained release tablets in cardiac patients.
    Kalin ML; Babich MF; Klinke WP; Hui WK
    Can J Cardiol; 1990; 6(1):15-8. PubMed ID: 2310989
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Oral administration of procainamide for ventricular arrhythmia. Plasma concentrations during use of tablets(Pronestyl) and a slow-release preparation (Porcainamide Durettes)].
    Bliddal J
    Ugeskr Laeger; 1976 Sep; 138(40):2425-33. PubMed ID: 968996
    [No Abstract]   [Full Text] [Related]  

  • 56. [The bioequivalence of two nifedipine sustained-release formulations after single administration in steady state].
    Meyer FP; Banditt P
    Arzneimittelforschung; 1993 Jun; 43(6):646-50. PubMed ID: 8352817
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Colonic bezoar caused by cracked-wheat consumption.
    Habibi M; Demirci E; Demirci R; Bulbuller N
    Saudi Med J; 2015 Feb; 36(2):252-3. PubMed ID: 25719596
    [No Abstract]   [Full Text] [Related]  

  • 58. [Bioequivalence of nifedipine sustained-release formulations in comparison to standard preparations in solid state].
    Herrmann R
    Arzneimittelforschung; 1996 Jan; 46(1):28-34. PubMed ID: 8821514
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oesophageal bezoar as a complication of enteral nutrition in critically ill patients. Two case studies.
    Gil-Almagro F; Carmona-Monge FJ
    Intensive Crit Care Nurs; 2016 Feb; 32():29-32. PubMed ID: 26531231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers.
    Cainazzo MM; Pinetti D; Savino G; Bartiromo M; Forgione A; Bertolini A
    Drugs Exp Clin Res; 2005; 31(3):115-21. PubMed ID: 16033250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.